Glenmede Trust Co. NA Buys 22,439 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Glenmede Trust Co. NA boosted its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 145.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,884 shares of the company's stock after purchasing an additional 22,439 shares during the period. Glenmede Trust Co. NA owned about 0.08% of Amphastar Pharmaceuticals worth $1,839,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its position in Amphastar Pharmaceuticals by 59.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 94,466 shares of the company's stock valued at $4,584,000 after acquiring an additional 35,284 shares during the period. Algert Global LLC bought a new position in Amphastar Pharmaceuticals during the 3rd quarter worth $3,217,000. Intech Investment Management LLC lifted its holdings in Amphastar Pharmaceuticals by 21.9% during the 3rd quarter. Intech Investment Management LLC now owns 12,989 shares of the company's stock worth $630,000 after buying an additional 2,331 shares during the period. Aurora Investment Counsel grew its position in shares of Amphastar Pharmaceuticals by 0.4% in the 3rd quarter. Aurora Investment Counsel now owns 54,698 shares of the company's stock valued at $2,654,000 after buying an additional 232 shares during the last quarter. Finally, Segall Bryant & Hamill LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at about $921,000. Institutional investors and hedge funds own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Up 1.5 %

NASDAQ:AMPH traded up $0.69 on Monday, hitting $45.88. The stock had a trading volume of 606,661 shares, compared to its average volume of 398,857. The company has a market cap of $2.21 billion, a PE ratio of 15.06, a P/E/G ratio of 0.90 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The business's fifty day moving average is $47.83 and its 200 day moving average is $44.56. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insider Activity

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 7,426 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $386,523.30. Following the completion of the transaction, the chief financial officer now owns 94,103 shares in the company, valued at approximately $4,898,061.15. The trade was a 7.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Yakob Liawatidewi sold 5,214 shares of the firm's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the transaction, the executive vice president now owns 74,938 shares in the company, valued at $3,900,522.90. This represents a 6.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,533 shares of company stock worth $1,378,252 over the last three months. 27.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. StockNews.com cut shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 price target on the stock. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $60.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.